LYCOS RETRIEVER 
Amylin Pharmaceuticals
built 220 days ago
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines for the treatment of diabetes, obesity and cardiovascular disease.. The company was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells of the pancreas that make insulin. Since then, Amylin has built a strong foundation on research and development. Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates. The company has amassed significant research and clinical expertise in metabolic medicine including the areas of diabetes, obesity and cardiovascular disease. By "Challenging Science," Amylin challenges conventional thinking to create innovative approaches to the discovery, development and commercialization of novel therapies for metabolic diseases.
Source:
Amylin Pharmaceuticals, Inc., incorporated on September 29, 1987, is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. The Company is marketing two first-in-class medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company has ongoing programs in pharmaceutical discovery and development, including a late-stage program to develop exenatide once weekly, to enable once weekly administration of exenatide for the treatment of type 2 diabetes. The Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. It ... has other early-stage programs for diabetes, obesity and other therapeutic areas. The Company maintains an active discovery research program focused on peptide therapeutics and is actively seeking to in-license additional drug candidates.
Source:
Amylin Pharmaceuticals Inc. (AMLN) opened at 26.20. So far today, the stock has hit a low of 24.55 and a high of 26.26. AMLN is now trading at 24.81, down 1.66 (-6.34%). The stock hit its 52 week high of 53.25 in August and set its 52 week low of 24.55 today. AMLN has been losing ground since September of last year. Shares of Amylin Pharmaceuticals have been plunging today on worries that new Food and Drug Administration requirements could delay approval of Amylin's long-acting diabetes drug exenatide LAR.
Source:
Amylin Pharmaceuticals Inc. (AMLN) opened at 49.83. So far today, the stock has hit a low of 49.14 and a high of 49.98. AMLN is now trading at 49.27, down 0.73 (-1.46%). The stock hit its 52 week high of 53.25 in August and set its 52 week low of 35.55 in January. AMLN rose at the beginning of the year, but has been moving sideways for the past two months. Amylin announced today that he Food and Drug Administration did not approve the use of the company's Symlin diabetes drug with basal insulin alone or with basal insulin without taking mealtime insulin.
Source:
Amylin Pharmaceuticals is engaged in the discovery and development of potential drug candidates for the treatment of metabolic disorders. They are developing SYMLIN for the treatment of people with diabetes who use insulin. Other drugs are currently in very early stages of development.
Source:
SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast a conference call on Wednesday, October 31, 2007 at 8:30 a.m. ET/5:30 a.m. PT to discuss today's release of the once-weekly exenatide long-acting release study results. Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead the call.
Source:
MORE ABOUT
Amylin Pharmaceuticals